Affordable Access

deepdyve-link
Publisher Website

Corticosteroids in the management of prostate cancer: a critical review.

Authors
  • Ndibe, Chukwuma
  • Wang, Christopher G
  • Sonpavde, Guru
Type
Published Article
Journal
Current treatment options in oncology
Publication Date
Feb 01, 2015
Volume
16
Issue
2
Pages
6–6
Identifiers
DOI: 10.1007/s11864-014-0320-6
PMID: 25762121
Source
Medline
License
Unknown

Abstract

Corticosteroids have been used in the management of prostate cancer for over 30 years. Although daily oral corticosteroids have frequently used in conjunction with chemotherapy for metastatic castration-resistant prostate cancer, their independent impact on survival is unclear. However, corticosteroids confer palliative benefits and are associated with objective responses and circulating tumor cell (CTC) and PSA declines in a small minority of patients, although toxicities such as osteoporosis and immunosuppression complicate long-term use. Following the demonstration of a palliative benefit for mitoxantrone combined with corticosteroids compared with corticosteroids alone, subsequent trials that demonstrated a benefit for first-line docetaxel over mitoxantrone, and second-line cabazitaxel over mitoxantrone, administered concurrent daily oral corticosteroids with all of these agents to maintain uniformity. Conversely, improved outcomes were demonstrated with docetaxel without corticosteroids for metastatic castration-sensitive prostate cancer. Daily oral corticosteroids are routinely combined with abiraterone to mitigate symptoms of mineralocorticoid excess. In contrast daily corticosteroids are not essential when administering enzalutamide or radium-223, and there is a concern of deleterious immune effects concurrently with sipuleucel-T. Given emerging evidence for promotion of resistance mechanisms, routine administration of daily oral corticosteroids in settings other than abiraterone administration and palliation of symptoms is probably not required.

Report this publication

Statistics

Seen <100 times